GSK And Reckitt Opting Out Of Pfizer's Consumer Business Sale Speaks Volumes
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Reckitt and GSK withdraw from negotiating on potential deals for with Pfizer's consumer business, leaving slim chances Pfizer will receive an acceptable offer from other drug firms mentioned as potential suitors for the business, which it has valued at around $20bn. A spin-off could move to the fore.